IMPERAGEN LIMITED

13761050
Active United Kingdom

Research and experimental development on biotechnology

12 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
I

IMPERAGEN LIMITED

13761050

Research and experimental development on biotechnology

Founded 23 Nov 2021 Active United Kingdom 12 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 12 May 2026 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 17 Apr 2026 Next due 14 Jan 10001 97088 months remaining
Net assets £2M £932K 2024 year on year
Total assets £2M £1,000K 2024 year on year
Total Liabilities £89K £67K 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Website

www.example.com

Full company profile for IMPERAGEN LIMITED (13761050), an active life sciences and medical technology company based in United Kingdom. Incorporated 23 Nov 2021. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type total-exemption-full
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Net Assets, Total Assets & Total Liabilities (2022–2024)

Cash in Bank

£598.56k

Decreased by £1.00M (-63%)

Net Assets

£1.52M

Decreased by £932.21k (-38%)

Total Liabilities

£89.01k

Decreased by £67.34k (-43%)

Turnover

N/A

Employees

12

Increased by 3 (+33%)

Debt Ratio

6%

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 1

Investors (2)

Investor NameInvestor SinceParticipating Rounds
Investor 1Aug 2022Seed
Investor 2Aug 2022Seed

Share Capital

Share Capital

Share allotments and capital structure

13 Allotments 187,879 Shares £6.15m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
17 Apr 2026327£26k£80.32
13 Apr 202641,531£3.34m£80.32
13 Apr 20264,831£388k£80.32
12 Sept 202516,504£1.02m£61.94
12 Sept 20252,868£178k£61.94

Officers

Officers

3 active
Status
Andrew AlmondDirectorBritishEngland5323 Nov 2021Active
Iq Capital Directors Nominees LtdCorporate-directorUnited KingdomUnknown28 Jul 2022Active
Timothy John EyesDirectorBritishEngland4423 Nov 2021Active

Shareholders

Shareholders (20)

Iq Capital Fund Iv A Lp
17.0%
28,838
Iq Capital Fund Iv A Lp
17.0%
28,838

Persons with Significant Control

Persons with Significant Control (0)

No PSC information available

Group Structure

Group Structure

No group structure identified

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
12 May 2026AccountsAnnual accounts made up to 31 Dec 2025
9 May 2026ResolutionResolutions
9 May 2026IncorporationMemorandum Articles
9 May 2026IncorporationMemorandum Articles
20 Apr 2026CapitalAllotment of shares (GBP 21.6786) on 17 Apr 2026
12 May 2026 Accounts

Annual accounts made up to 31 Dec 2025

9 May 2026 Resolution

Resolutions

9 May 2026 Incorporation

Memorandum Articles

9 May 2026 Incorporation

Memorandum Articles

20 Apr 2026 Capital

Allotment of shares (GBP 21.6786) on 17 Apr 2026

Recent Activity

Latest Activity

Annual accounts made up to 31 Dec 2025

1 months ago on 12 May 2026

Resolutions

1 months ago on 9 May 2026

Memorandum Articles

1 months ago on 9 May 2026

Memorandum Articles

1 months ago on 9 May 2026

Allotment of shares (GBP 21.6786) on 17 Apr 2026

2 months ago on 20 Apr 2026